Business Context and Reporting Period
This Form 8-K Current Report was filed by Enochian Biosciences, Inc. (not Lunai Bioworks Inc.) on March 31, 2020, reporting events occurring on March 27, 2020. The registrant is a Delaware corporation with its principal executive offices in Los Angeles, CA, and its common stock trades on The Nasdaq Stock Market under the symbol ENOB.
Key Financial Metrics and Transaction Details
The filing discloses a specific financing transaction rather than periodic financial results (revenue, profit, or cash flow).
- Debt Obligation: Entered into a $5,000,000 unsecured, non-convertible debt agreement.
- Lender: Paseco ApS, a Danish limited company and existing stockholder.
- Interest Rate: Fixed at 6% per annum.
- Maturity Date: November 30, 2021.
- Interest Payment: Interest was prepaid in full on the issuance date (March 30, 2020) via the issuance of 188,485 shares of common stock.
- Liquidity Impact: The filing does not provide current cash balance or liquidity ratios, only the terms of the new debt instrument.
Material Changes
The primary material change is the creation of a direct financial obligation of $5,000,000. The filing does not provide comparative financial data (e.g., prior period revenue or debt levels) to quantify changes in margins or profitability.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding future operations. The transaction was executed pursuant to exemptions from registration under Regulation S and Section 4(a)(2) of the Securities Act of 1933. The Note and Purchase Agreement contain customary representations, warranties, and covenants, the full text of which are referenced in the exhibits.
Investor Verification Checklist
- Verify the company name discrepancy: The filing is for Enochian Biosciences, Inc., not Lunai Bioworks Inc.
- Confirm the dilution impact of the 188,485 shares issued to prepay interest.
- Review the full text of the Note Purchase Agreement (Exhibit 10.1) and Promissory Note (Exhibit 10.2) for specific covenants and default provisions.
- Check subsequent filings for the actual cash proceeds received, as the filing describes the agreement but does not explicitly state the cash amount received versus the principal.